2002
DOI: 10.1159/000070746
|View full text |Cite
|
Sign up to set email alerts
|

Development of Synthetic Pan-Selectin Antagonists: A New Treatment Strategy for Chronic Inflammation in Asthma

Abstract: Asthma is characterized by chronic inflammation of large and small airways maintained by extravasation of leukocytes from the bloodstream into the surrounding peribronchial tissue. The process of extravasation is of crucial importance in inflammation and is mediated by a sequenced and concerted action between different adhesion molecules on endothelial cells and ligands on leukocytes. In this context, initial rolling and tethering is generally considered to be the primary event which is mediated by selectins, … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
25
0

Year Published

2003
2003
2013
2013

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(25 citation statements)
references
References 26 publications
0
25
0
Order By: Relevance
“…Structural mimetics of selectin ligands have been described to block selectin ligand function under in vitro conditions (Kogan et al, 1998). This may open a new and interesting avenue to manipulate selectin-dependent rolling in vivo (Aydt and Wolff, 2002).…”
Section: Manipulation Of Selectin-dependent Leukocyte Rollingmentioning
confidence: 99%
“…Structural mimetics of selectin ligands have been described to block selectin ligand function under in vitro conditions (Kogan et al, 1998). This may open a new and interesting avenue to manipulate selectin-dependent rolling in vivo (Aydt and Wolff, 2002).…”
Section: Manipulation Of Selectin-dependent Leukocyte Rollingmentioning
confidence: 99%
“…This pan-selectin antagonist has been successfully investigated in different preclinical models of inflammatory diseases such as psoriasis, asthma and reperfusion injury [17]. Bimosiamose is at present the most advanced small molecule selectin inhibitor in development [18]. It is in a phase IIa clinical trial for the treatment of allergic asthma, where a single intravenous administration improves several disease parameters such as decreasing eosinophil airway recruitment [18].…”
Section: Selectin Inhibitorsmentioning
confidence: 99%
“…pearance or up-regulation of CAMs has been observed in a variety of central nervous system (CNS) diseases (5)(6)(7)(8) and the therapeutic approaches blocking leukocyte-endothelium interactions have provided encouraging results, suggesting that these molecules have a pivotal role (9)(10)(11)(12)(13).…”
Section: T Tanriverdi Et Almentioning
confidence: 99%